79 related articles for article (PubMed ID: 14506684)
21. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
[TBL] [Abstract][Full Text] [Related]
22. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Gray MD; Mann M; Nitiss JL; Hendershot LM
Mol Pharmacol; 2005 Dec; 68(6):1699-707. PubMed ID: 16141312
[TBL] [Abstract][Full Text] [Related]
23. Both alpha and beta isoforms of mammalian DNA topoisomerase II associate with chromosomes in mitosis.
Null AP; Hudson J; Gorbsky GJ
Cell Growth Differ; 2002 Jul; 13(7):325-33. PubMed ID: 12133901
[TBL] [Abstract][Full Text] [Related]
24. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
[TBL] [Abstract][Full Text] [Related]
25. Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.
Jonstrup AT; Thomsen T; Wang Y; Knudsen BR; Koch J; Andersen AH
Nucleic Acids Res; 2008 Nov; 36(19):6165-74. PubMed ID: 18824478
[TBL] [Abstract][Full Text] [Related]
26. The effect of 5-aminolevulinic acid-based photodynamic treatment (PDT) on nucleoli of leukemic granulocytic precursors represented by K562 blastic cells in vitro.
Smetana K; Pluskalová M; Marinov Y; Hrkal Z
Med Sci Monit; 2004 Nov; 10(11):BR405-9. PubMed ID: 15507844
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of topoisomerase IIalpha to rapidly evaluate cell proliferation in brain tumors.
Oda M; Arakawa Y; Kano H; Kawabata Y; Katsuki T; Shirahata M; Ono M; Yamana N; Hashimoto N; Takahashi JA
Biochem Biophys Res Commun; 2005 Jun; 331(4):971-6. PubMed ID: 15882973
[TBL] [Abstract][Full Text] [Related]
28. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
Sakaguchi A; Kikuchi A
J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
[TBL] [Abstract][Full Text] [Related]
29. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
30. Alternariol acts as a topoisomerase poison, preferentially affecting the IIalpha isoform.
Fehr M; Pahlke G; Fritz J; Christensen MO; Boege F; Altemöller M; Podlech J; Marko D
Mol Nutr Food Res; 2009 Apr; 53(4):441-51. PubMed ID: 18727009
[TBL] [Abstract][Full Text] [Related]
31. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
32. An antigen recognized on cells in apoptosis detected by monoclonal antibody 2E12.
Stibríková G; Marinov I; Stöckbauer P
Neoplasma; 2005; 52(1):18-24. PubMed ID: 15739021
[TBL] [Abstract][Full Text] [Related]
33. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
34. Discrimination of live and early apoptotic mononuclear cells by the fluorescent SYTO 16 vital dye.
Sparrow RL; Tippett E
J Immunol Methods; 2005 Oct; 305(2):173-87. PubMed ID: 16165150
[TBL] [Abstract][Full Text] [Related]
35. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
[TBL] [Abstract][Full Text] [Related]
36. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
37. Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells.
Wang L; Sun J; Li YQ; Chen ZS; Akiyama S; Xian LJ
Anticancer Drugs; 2007 Oct; 18(9):1015-21. PubMed ID: 17704651
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
39. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
40. Morphological assessment of apoptosis.
Doonan F; Cotter TG
Methods; 2008 Mar; 44(3):200-4. PubMed ID: 18314050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
